The treatment of hypertension with reserpine is described. When used alone it produced adequate falls of blood pressure in ten out of forty patients. The combination of reserpine with veratrum did not increase the hypotensive effects of reserpine alone. The combination of reserpine with pentapyrrolidinium increases the effectiveness of the pentapyrrolidinium and lessens its parasympathetic side effects. The combination of reserpine and pentapyrrolidinium is regarded as the best therapeutic regime for severe hypertension. Some These studies have indicated that in part at least, the hypotensive action of reserpine is mediated through the sympathetic nervous system. Our own studies7 have also shown that in rabbits reserpine has a direct vasodilating action on the blood vessels and suggest that there may be some direct effect in man. In a previous report from this department8 the effects of large doses of reserpine in man were described, and further clinical studies have been published
The treatment of hypertension with reserpine is described. When used alone it produced adequate falls of blood pressure in ten out of forty patients. The combination of reserpine with veratrum did not increase the hypotensive effects of reserpine alone. The combination of reserpine with pentapyrrolidinium increases the effectiveness of the pentapyrrolidinium and lessens its parasympathetic side effects. The combination of reserpine and pentapyrrolidinium is regarded as the best therapeutic regime for severe hypertension. Some mild cases of hypertension may be managed with reserpine alone.
E XTRACTS of Rauwolifa serpentina have been extensively used in India for several decades in the treatment of a variety of conditions including hypertension.' Their value in treatment of the latter condition has recently attracted world-wide interest. The particular activity as a hypotensive agent of reserpine, an alkaloid of Rauwolfia isolated by Swiss workers2 has been investigated in animals by Bein and asso- ciates,3' 4 Trapold and co-workers,5 Plummer and colleagues, 6 and McQueen and associates.7 These studies have indicated that in part at least, the hypotensive action of reserpine is mediated through the sympathetic nervous system. Our own studies7 have also shown that in rabbits reserpine has a direct vasodilating action on the blood vessels and suggest that there may be some direct effect in man. In a previous report from this department8 the effects of large doses of reserpine in man were described, and further clinical studies have been published by Loffler and co-workers9, Wilkins, 10' 11 Freis and The use of Rauwolfia alkaloids in combination with other hypotensive agents has been reported on by Wilkins'0 (Serpina and Apresoline), Wilkins and Judson'6 (Serpina and veratrum alkaloids) and Ford and Moyer'7 (Rauwiloid and hexamethonium). A preliminary account'8 has outlined in general terms our own experiences with a combination of reserpine and pentapyrrolidinium. At that time it could be stated that of 40 cases, distinctive benefits had resulted from the use of the combination in 27 (8 classified as very good and 19 as good). Benefit was apparent either in an important decrease of side effects or in improvement in the degree of blood pressure control without increase of side effects, or in a combination of these. Eight were classed as fair, meaning that some specific advantage had been obtained by the combination although this might be of slight degree. In only 5 out of 40 were the results considered poor. It was pointed out that an important advantage of the combination of reserpine and pentapyrrolidinium is that the dose of the latter is smaller than would be needed if it were used alone to produce an equal hypotensive action.
In the present report the results are presented of using reserpine alone in tolerable doses in 40 cases, reserpine in combination with pentapyrrolidinium in 66 cases, with hexamethonium in 9 cases, and in combination with alkaloids of veratrum in 10 cases.
RESULTS

Reserpine Alone
Reserpine in doses of 9 mg. daily will reduce the blood pressure in most hypertensive subjects.8 Such large doses are accompanied by side effects of a degree of severity such as to make their use as a form of continuous therapy impractical. In a certain number of cases, however, the blood pressure is substantially reduced at a dosage level low enough to avoid serious side effects (0.5 to 1.5 mg. per day). We have given 40 patients a trial of therapy with reserpine alone in this dosage. In 10 of these blood pressure control was sufficiently good for it to be used as the treatment of choice. In several further patients good falls were obtained with low doses but blood pressure control was not as satisfactory as could be obtained by the addition of small amounts of another hypotensive agent, usually pentapyrrolidinium. The "Range of Blood Pressure" refers to the highest and lowest readings recorded during a day spent in the clinic. The cases were of all degrees of severity including cases of malignant hypertension. Of the 69 cases, the result of introduction of the combined therapy is now considered very good in 15 cases and good in 20 cases, distinctive benefits having resulted from the addition of reserpine either in an important decrease of side effects or in improvement in the degree of blood pressure control without increase of side effects, or in a combination of these. In 18 the result is classed as fair, some specific advantage having been gained, though this might be of slight degree. Thus, in 53 of the 69 cases the addition of reserpine to the methonium compound in use is considered to have improved the treatment. Sixteen were no better or were worse.
An important advantage from the use of reserpine in combination with pentapyrrolidinium is the extent to which the dose of the latter may be diminished for an equal or greater hypotensive effect on addition of reserpine. Patients stabilized on pentapyrrolidinium usually remark on an increased hypotensive effect from their usual dose within 48 hours of the addition of reserpine. They are warned to expect this and told to reduce the dose of pentapyrrolidinium by progressive decrements (see table 4) until they reach that at which the hypotensive effect at its maximum is tolerable. The severity of parasympathetic side effects is usually reduced proportionally to the fall in methonium dosage. Additionally, in many cases the maximum blood pressure readings permitted by the regimen are significantly lowered. Although the extremes of variation of blood pressure seen with hexamethonium are better controlled with pentapyrrolidinium, some effect of the latter usually still being manifest even 12 hours after the last dose, high peaks may still be encountered. These high (and undoubtedly dangerous) peaks are notably diminished after addition of reserpine.
Side effects from the reserpine are frequent but with the small doses used are seldom a source of serious inconvenience. They have already been detailed in the section on reserpine The Combination of Reserpine with Veratrum In 10 cases an extended trial was undertaken of reserpine combined with veratrum. In two of these this mixture is being used as the definitive form of treatment, but in only one has it seemed to give optimum results. In the others the degree of blood pressure control at dose levels at which side effects of the veratrum (nausea and vomiting) were tolerable was inferior to that which could be obtained either with reserpine and pentapyrrolidiniium or with the latter alone. The results of the reserpine-veratrum regimen are shown in table 3.
DISCUSSION
Our object in treating hypertensive patients is to reduce the blood pressure to as near normal as possible, for as much of the 24-hour day as can be achieved, and our assessment of the therapeutic value of hypotensive drugs is an assessment of the degree of safe blood pressure reduction which can be obtained without intolerable side effects. We have used these criteria in examining the efficacy of reserpine, alone and in combination with pen tapyrrolidinium and with veratrum alkaloids.
Reserpine alone sometimes produces large blood pressure falls but usually only in doses which are accompanied by severe side effects. When smaller doses are used, the side effects are generally less conspicuous, but with such doses we have been able to obtain an adequate hypotensive action in only one-fourth of our patients. Those in whom an adequate control could be achieved by the use of reserpine alone were generally the milder cases, and often, though not invariably, they had low basal blood pressures. Even with the low doses used we have encountered some difficulties from side effects, particularly in the aggravation of symptoms in subjects with bronchial asthma, ulcerative colitis, gallstones and pre-existing mental depression. Further, we have found that in patients with hypertensive heart failure blood pressure reduction by reserpine does not improve breathlessness as with a corresponding reduction by pentapyrrolidinium.
We have examined the effects of combining reserpine with various preparations of veratrum. Our particular interest was to determine whether the addition of reserpine enabled a greater degree of blood pressure reduction to be obtained without the development of vomiting or other side effects of veratrum. The results have been disappointing. In 10 patients the addition of reserpine did not alter the dose of veratrum which led to vomiting, and subtoxic doses of veratrum were not found to exert any distinctively greater hypotensive effect after the addition of reserpine than they did before. We have concluded that the combination of reserpine with veratrum is not a satisfactory means of treating hypertension.
The combination of reserpine with pentapyrrolidinium has also been studied. Pentapyrrolidinium is a substance chemically related to hexamethonium, but, unlike hexamethonium, it can be safely and effectively given by mouth in most patients. It shares with hexamethoniium the disadvantage that blockade of the sympathetic ganglia sufficient to induce a useful blood pressure fall cannot usually be obtained without parasympathetic ganglionic blockade also occurring. Although the hypotensive action of pentapyrrolidinium is more prolonged than that of hexamethonium, the blood pressure usually rises to hypertensive levels by the time that the next dose is due to be taken. We have examined the result of combining reserpine with pentapyrrolidinium, with special reference to the incidence of parasympathetic side effects, and also to determine whether the combination of drugs gave a more consistent and smooth hypotensive effect. The results of combining the two drugs have been encouraging. In 53 out of 69 cases in whom the combination was examined, it was possible to produce a better control over the blood pressure with less side effects. In those previously taking pentapyrrolidinium alone, the addition of reserpine made it necessary to reduce the dose of pentapyrrolidinium. In some instances the dose of pentapyrrolidinium required was less than half that previously needed. The greater the reduction in dose of pentapyrrolidinium the greater was the reduction of side effects due to parasympathetic blockade. In a few it had been difficult to maintain fully effective hypotensive therapy with pentapyrrolidinium alone because of the severity of the side effects, and in these, a striking improvement in the degree of control has usually been obtained by the combination with reserpine.
Over the past four and one-half years we have studied the therapeutic value of the methonium compounds, the veratrum alkaloids, 1-hydrazinophthalazine (Apresoline), the hydrogenated ergot alkaloids, the adrenolytic agents such as Dibenzyline, and reserpine. Of these the combination of reserpine and pentapyrrolidinium appears to be distinctively the most effective means of controlling the blood pressure. Where there is no special urgency about the institution of hypotensive therapy, we now give reserpine in doses of 0.5 mg. thrice daily for a period of about 14 days. No special observation is required during this period since reserpine has the advantage that the dose in the therapeutic range is not immediately critical, in contrast to the extreme accuracy of the dose required when the methonium compounds or the veratrum alkaloids are used. This obviates the need for the close control of dosage so necessary with the latter drugs. In the small dose range, variations in the dose of reserpine of up to 0.5 mg. daily are not accompanied by noticeable variations in the immediate hypotensive effect. At the end of this time a few will be found to have a satisfactorily controlled blood pressure. In our experience these amount to about one in four and are generally the milder cases. In the remainder it For patients with hypertensive heart failure, or for those with malignant hypertension, reserpine is never adequate alone, and in these patients we commence treatment with pentapyrrolidinium and reserpine in combination.
The duration of treatment with the combination of reserpine and pentapyrrolidinium has been less than six months in all our patients, so that there has been insufficient time to determine whether the long-term effects of treatment will be better than with pentapyrrolidinium alone.
SUMMARY AND CONCLUSIONS
The clinical use of the alkaloid reserpine in the treatment of hypertension has been studied in 85 hypertensive subjects.
In doses with few side effects, the hypotensive action of reserpine alone produced therapeutically useful falls of blood pressure in 10 out of 40 patients.
The administration of veratrum alkaloids to patients already taking reserpine did not produce any further significant hypotensive effects except in toxic doses.
The administration of reserpine in combination with pentapyrrolidinium to subjects previously taking the latter substance alone, led to an improvement in the hypotensive action, with a reduction in the severity of side effects due to parasympathetic blockade.
It is concluded that the combination of reserpine and pentapyrrolidinium is the most satisfactory means at present available of treating severe hypertension, although some 
